Why The British American Tobacco Investment In OrganiGram Is Important
OrganiGram Holdings Inc’s (NASDAQ: OGI) stock is likely to re-rate following the investment by a subsidiary of British American Tobacco PLC (NYSE: BTI), according to Cantor Fitzgerald.
The OrganiGram Analyst: Pablo Zuanic maintained an Overweight rating for OrganiGram Holdings, while raising the price target from C$3.50 to C$6.
The OrganiGram Thesis: The latest deal for a 19.9% stake in OrganiGram makes British American Tobacco the third tobacco company to invest in cannabis, Zuanic said in the note.
“We think the OGI stock valuation should now reflect the potential for BATS to increase its stake in the future as well as a strengthened B/S that provides M&A optionality, room for potential international collaboration, and the potential for OGI to further bolster its already well-recognized product development and innovation capabilities,” he wrote.
“Following the C$221Mn investment, OGI will have cash holdings and short-term investments of C$296Mn, according to management. Only C$30Mn of the C$296Mn is to go for joint product development, so OGI should also have enhanced ability for M&A,” the analyst said.
OGI Price Action: Shares of OrganiGram had declined by 5.32% to $3.82 at the time of publication Friday.
(Image: OrganiGram Holdings)
Latest Ratings for OGI
Mar 2021 | BMO Capital | Downgrades | Market Perform | Underperform |
Jan 2021 | Canaccord Genuity | Downgrades | Speculative Buy | Hold |
Dec 2020 | Cantor Fitzgerald | Maintains | Overweight |
View More Analyst Ratings for OGI
View the Latest Analyst Ratings
See more from Benzinga
Power Tools and Stimulus Fuels Stanley Black & Decker Upgrade
Mizuho Bullish On Tesla, Nio Stock: What EV Investors Need To Know
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
